COMBATING
BIOTERRORISM
Student Author

Tyshia Gwin is a senior majoring in
Cell, Molecular, and Developmental
Biology with a minor in C
 hemistry.
She has worked in Dr. David
Sanders’ laboratory for four years
and began her work on viruses
in spring of 2009 when she was
awarded the Homeland Security
Science, Technology, Engineering,
and Mathematics Career Development Fellowship for research
in bioterrorism. Outside of research, she is a tutor for
the Biology Resource Center and an ambassador for
the Biology Department. Starting this fall, she will be
attending graduate school at Harvard University to obtain
a Ph.D. in Virology.

Faculty Mentor
Dr. David Sanders is an associate
professor of Biological Sciences at
Purdue University. He received his
Bachelor of Science degree from
Yale College in Molecular Biophysics and Biochemistry. He conducted
his Ph.D. research in Biochemistry
with Dr. Daniel E. Koshland, Jr.,
who was then editor of the journal Science, at the University of
California at Berkeley. Dr. Sanders
joined the Markey Center for Structural Biology at Purdue
University in 1995, where he is the leader of the Molecular Virology program and also a member of the Cancer
Center. He was the discoverer of a biochemical reaction
that leads to the entry of cancer-causing retroviruses into
cells. His work on the Ebola virus led to his participation
in the U.S. Defense Threat Reduction Agency’s Biological
Weapons Proliferation Prevention Program, a product of
the Nunn-Lugar legislation. Dr. Sanders is a recipient of
the National Science Foundation CAREER Award and an
American Cancer Society Research Scholar.

16

Abstract

Outbreaks of the Venezuelan Equine Encephalitis Virus
(VEEV) and the Chikungunya Virus (CHIKV) continue to
emerge in Central and South America, Africa, and Asia, but
there are currently no vaccines or anti-virals for these viruses.
Given their ease of transmission, debilitating symptoms, and
genetic alterability, VEEV and CHIKV have great potential
for development into biological weapons. Therefore, there
is an urgent need to determine possible methods of treatment or prevention. One possibility of prevention lies in
determining the structure and biological function of the E3
protein that plays a key role in the infectivity of the viruses.
In this research, heavy nitrogen (N15) labeling and nickelaffinity purification were used to purify E3 from VEEV. The
labeled E3 was used in nuclear magnetic resonance (NMR) to
determine secondary structure, but protein aggregation resulted
in poor signal. Although various purification techniques,
including cobalt-affinity purification, were used to obtain small
amounts of E3 protein from CHIKV, further work is needed in
order to obtain enough protein to be used for NMR analysis.
Gwin, T. (2011). Combating bioterrorism: Purification and
structural analysis of the E3 proteins of the Venezuelan Equine
Encephalitis virus and the Chikunguya virus, Journal of Purdue
Undergraduate Research, 1, 16 – 21. doi: 10.5703/jpur.01.1.3
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COMBATING BIOTERRORISM:

Purification and Structural Analysis of the E3 Proteins of the
Venezuelan Equine Encephalitis Virus and the Chikungunya Virus
Tyshia Gwin, Cell, Molecular, and Developmental Biology
Image 1. Surface of the Venezuelan Equine Encephalitis Virus. The spikes seen on the surface (yellow) are responsible
for the virus binding to the host cell. A matrix of proteins (blue) surrounds the virus core, which contains the genome
needed for virus production inside the host cell (Paredes, Alwell-Warda, Weaver, Chiu, & Watowich, 2001, p. 9534).
Reproduced with permission from American Society of Microbiology.

INTRODUCTION
Origin and history
The Venezuelan Equine Encephalitis Virus (VEEV)
infects both equines and humans and was first reported
in donkeys, mules, and horses in the 1930s in South
America. Human cases were first documented in the
1950s when a small outbreak occurred in Colombia
(Sanmartin-Barberi, Groot, & Osorno-Mesa, 1954, p.
283). Viral outbreaks were localized to the regions of
northern South America until the 1990s when the virus
began to spread into Central America, and outbreaks
have since been reported as far north as Mexico (Weaver,
Ferro, Barrera, Boshell, & Navarro, 2004, p. 146).
The first case of the Chikungunya Virus (CHIKV) was
reported in humans in 1953 in Tanzania (Powers, Brault,
Tesh, & Weaver, 2000, p. 471). Outbreaks o ccurred
throughout the 1960s and 1980s in several regions of
Africa, and it is suggested that the virus spread to Asia
as several outbreaks arose concurrently (Powers, et al.,
2000, p. 471). In the 2000s, cases have been reported
in various other regions including Europe, North
America, and Australia (Powers & Logue, 2007, p. 2365).
Recently, large epidemics in India have caused concern
about the growing rate of incidence (Pialoux, Gauzere,
Jauréguiberry, & Strobel, 2007, p. 319).
Although their mortality rates are low, each of these
viruses causes health problems including rash, fever,
arthritis, nausea, diarrhea, weakness, and fatigue, which
often last for weeks (Weaver et al., 2004, p. 151). Because
of their ability to incapacitate the infected, as well as

the ease with which they can be genetically altered and
transmitted, VEEV and CHIKV could easily be used as
biological weapons. In 1959, Soviet scientists developed
VEEV as a bioweapon and demonstrated the efficiency of
aerosol transmission of the virus (Croddy, 2001, p. 211).
Existing treatments of the infection focus on alleviating
symptoms, but additional research could determine
possible methods of preventing infectivity. In order for
the viruses to infect cells, the E3 protein of the viruses
must be separated from the precursor protein known as
pE2. The E3 protein acts as a natural inhibitor to virus
penetration into cells; however, the biological function
and three-dimensional structure of the E3 protein in
VEEV and CHIKV is not known. Through determining
the structure of the E3 protein, information on function
could be obtained, or similar inhibitory molecules could
be synthesized to prevent infection.

Infection
Both VEEV and CHIKV are transmitted by mosquitoes,
and symptoms begin to appear soon after the onset of
infection. Most of the symptoms subside after a few days,
but weakness can last for several weeks, and infection with
VEEV can progress to encephalitis (Weaver et al., 2004, p. 151).

Alphaviruses
VEEV and CHIKV are alphaviruses, which are m
 embers
of the Togaviridae family of viruses (Jose, Snyder, &
Kuhn, 2009, p. 837). The alphaviruses are categorized
as Old World or New World viruses. Old World viruses
combating bioterrorism
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include Semliki Forest, Sindbis, and Chikungunya,
which cause symptoms such as rash, fever, arthritis,
and weakness. New World viruses include Western
Equine Encephalitis, Eastern Equine Encephalitis, and
Venezuelan Equine Encephalitis. These share the same
symptoms as the Old World viruses, but can cause
encephalitis in the host (Jose, Snyder, & Kuhn, 2009, p. 837).
The viruses in the alphavirus family share many structural
similarities. Each alphavirus has an RNA genome that
encodes four nonstructural proteins and the capsid, E1, E2,
E3, and 6K proteins. The virus core, called the nucleocapsid,
contains the genome surrounded by a lattice of capsid
proteins (Jose, Snyder, & Kuhn, 2009, p. 841). A lipid bilayer
taken from the host cell during virus release surrounds the
nucleocapsid (Jose, Snyder, & Kuhn, 2009, p. 838). Inserted
into the bilayer are the viral glycoproteins E1 and E2, which
form 80 spikes on the virus surface (Paredes et al., 1993, p. 9096).
When the virus infects a cell, a cellular structure called the
endosome contains the nucleocapsid. After the virus has
entered the host cell, the nonstructural proteins are formed
using the information in the viral genome. The nonstructural
proteins replicate the genome and aid in the production of
the capsid, E1, E2, E3, and 6K proteins. Initially, the E3
and E2 proteins are linked and are called pE2. pE2 and E1
pair up to form heterodimers or pE2/E1 pairs (Jose, Snyder,
& Kuhn, 2009, p. 839). The pE2/E1 heterodimers are then
moved through the cell to be displayed on the plasma
membrane, or cell surface, of the host. At some point during
movement, pE2 is separated into the E3 and E2 proteins
(Strauss & Strauss, 1994, p. 504). At the plasma membrane,
the E1/E2 heterodimers combine in groups of three that
protrude from the virus and resemble spikes (Paredes et al.,
1998, p. 1538). Then the newly formed nucleocapsid buds
from the host cell, taking part of the host’s lipid bilayer
(plasma membrane) containing the E1/E2 glycoproteins
(Jose, Snyder, & Kuhn, 2009, p. 838). The mature virus can
then infect another cell. Part of the E1 protein, called the
fusion peptide, is responsible for nucleocapsid release from
the endosome and occurs as a result of E2 dissociating from
E1 in the acidic environment of the endosome. This process
releases the nucleocapsid into the cell, and viral replication
and protein production begins again.

The E3 protein
Although it is not well studied, the E3 protein appears to
act as a natural inhibitor to viral entry and infectivity. The
E3 protein, after separation from E2, is a small protein
roughly 7 kilodaltons in size (which is equal to approximately 100 quintillionth of a gram). The function of E3
has not been entirely determined, but it is likely that it is
needed for stabilization of the E1/E2 heterodimers during
movement to the cell surface (Jose, Snyder, & Kuhn,
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2009, p. 839). If E3 is removed from E2 prematurely, then
the E1/E2 heterodimers will dissociate and the progeny
viruses will lack the E1/E2 spikes, preventing them from
infecting other cells (Lobigs & Garoff, 1990, p. 1233).
The conformation of the pE2/E1 heterodimers protects the
fusion peptide of E1 from premature exposure; however,
when E3 is separated from E2 the conformation of E2
changes and causes exposure of the fusion peptide (Voss
et al., 2010, p. 711). These findings indicate that separation
of E3 from E2 is necessary for exposure of the fusion
peptide. If pE2 is not separated into E2 and E3, it can
still be incorporated into the spikes displayed on the
virus s urface (Strauss & Strauss, 1994, p. 504). Because
the fusion peptide of E1 is not exposed, the infectivity is
very low (Strauss & Strauss, 1994, p. 504), resulting in no
progeny virus production.
The reemergence of VEEV and CHIKV and the growing
rate of incidence have caused great concern. Due to the
ease of aerosol transmission, disease duration, and lack of
prevention or treatment, the viruses pose a threat for use
as biological weapons. If large numbers of a population
were infected, the severity of the symptoms could have a
dramatic impact on the health and economy of a c ountry.
For this reason, the study of the virus’ methods of
infectivity, particularly in regards to the significance of
E3 in infection, is crucial.
The aim of this research is to determine the structure of
the E3 protein from VEEV and CHIKV. Knowledge of the
E3 structure would also provide insight into the related
viruses of the alphavirus genus and could potentially
be used to design a structurally similar drug that could
prevent infection of the viruses in the same manner as E3.
Additionally, the function and fate of E3 after cleavage
from E2 is unclear, but structure can sometimes provide
valuable information regarding the function of a protein.
In order to learn about the structure and function of the
E3 protein, protein purification techniques including
nickel-affinity purification, cobalt-affinity purification,
and anion-exchange purification were used to isolate
large amounts of purified E3 to be used in the structural
analysis via nuclear magnetic resonance (NMR).

MATERIALS AND METHODS
Expression of the E3 protein
In order to obtain the E3 proteins from VEEV and
CHIKV to do structural studies, the first task was to use a
system to produce large amounts of the protein. Because
of the hazards and difficulties in obtaining the protein
from the viruses, a system was designed to produce the
protein in E.coli. Because of the internal environment
of the E.coli cells, the E3 protein could not be produced

without a protein that would add stabilization. To
accomplish this, the DNA sequence that encodes the E3
protein as well as the sequence that encodes thioredoxin,
a stabilizing protein, were linked and put into E.coli
cells. Contained within the thioredoxin (Trx) sequence
is a sequence for a his-tag (6XHis), which aids in the
purification of proteins from cells. The DNA sequence was
put into E.coli cells, and the cells were forced to produce,
or express, the protein. Large amounts of the recombinant
protein (see Figure 1), which also contains a recognition
sequence for TEV protease, were expressed in E.coli.

Purification of the E3 protein
Because E.coli normally expresses many different
proteins, the recombinant protein needed to be separated
from the other proteins (see Figure 2). To accomplish
this, the recombinant protein was isolated from E.coli
by passing it through a nickel column. This process is
called nickel-affinity purification. After the E.coli cells
expressed large amounts of the recombinant protein, they
were broken open, or lysed. The contents, which contained
normal E.coli proteins, the recombinant protein, and DNA
and RNA, were applied to a column containing nickel.
In order to separate the thioredoxin protein (Trx) from
the E3 protein, TEV protease was added to the protein,
which cuts the linker region between Trx and E3 protein.
After cleavage with TEV, the proteins were added onto
the nickel column again, but because the E3 protein then
lacked the 6XHis tag, it was able to pass through the
column and be collected.

Figure 1. Diagram of the recombinant protein. The
recombinant protein contains thioredoxin protein (Trx) for
stabilization of E3 in E.coli, a 6XHis tag for purification, a TEV
cut site, or cleavage site, for separation from Trx and 6XHis,
and the E3 protein.

RESULTS AND DISCUSSION
Expression and purification of the recombinant
protein from VEEV
To produce large amounts of the recombinant
protein containing E3 from VEEV, referred to as
VEEVTrx-6XHis-E3, the DNA sequence for VEEVTrx-6XHis-E3
was put into E.coli cells, and the cells were forced to
express VEEVTrx-6XHis-E3 for two hours at 37°C. After
expression, the cells were lysed, and the contents,
called the lysate, were applied to a nickel column. After
removal from the column, the purified VEEVTrx-6XHis-E3
was incubated with TEV protease for 16 hours at room
temperature. The mixture of proteins was then applied
to a nickel column, and the E3 protein (referred to as
VEEVE3) was collected and subsequently purified on an
anion-exchange column (see Figure 3).

Expression, purification, and structural analysis
of heavy nitrogen labeled VEEVE3

Figure 2. Diagram of nickel-affinity purification.
Left: The contents of the E.coli cells, called the lysate, which
include DNA, RNA, normal E.coli proteins, and the recombinant
protein, are added to a column that contains nickel. The 6XHis
of the recombinant protein binds tightly to the nickel and
remains stuck inside the column while the other cell components
lack 6XHis and can pass through and are discarded. The
recombinant protein is then removed from the column.
Middle: The E3 protein needs to be separated from the
thioredoxin protein (Trx) and 6XHis in order to do structural
analysis. TEV protease is added to the recombinant protein,
which cuts, or cleaves, the protein into Trx-6XHis and E3.
Right: The reaction mixture of TEV protease, Trx-6XHis, and
E3 is added to a nickel column. TEV protease also c ontains
6XHis and will stick to the column along with Trx-6XHis, while
the E3 protein does not and will pass thought the column
and can be collected. The now purified E3 can be used for
structural analysis.

Since large amounts of pure VEEVE3 were obtained,
structural work could be started. In order to use NMR
to determine the structure, the VEEVE3 had to be heavy
combating bioterrorism
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nitrogen (N15) labeled. In order to label the protein, it
was expressed in a minimal media supplemented with
N15, so that all of the amino acids of the recombinant
protein would be labeled. The labeled recombinant
protein, referred to as VEEVTrx-6XHis-E3-N15, was expressed
in minimal media supplemented with N15 for two hours
at 37°C, then for an additional 20 hours at 22°C. The
VEEVTrx-6XHis-E3-N15 was then purified through nickelaffinity purification. The purified VEEVE3-N15 was used
to perform a HSQC, which determines secondary protein
structure. The measurements were made at 4°C (see Figure 4).

37°C for four hours and was purified using nickel-affinity
purification. CHIKVTrx-6XHis-E3 was cleaved with TEV for
16 hours at room temperature and applied to a nickel
column and CHIKVE3 was collected (see Figure 5).

In the figure, the signal is tightly clumped. This indicates
that VEEVE3-N15 has aggregated, and as a result no
information about the secondary structure could
be determined. Investigation into different solution
conditions (buffers) and additives is needed to prevent
aggregation, so that a better HSQC can be obtained.

There are several possibilities as to why low yields
of CHIKVE3 were obtained. The possibilities of low
concentration and purity of TEV and CHIKVTrx-6XHis-E3,
as well as buffer conditions for the reaction, were tested
and resulted in little improvement in the efficiency of the
reaction. This led to the conclusion that that CHIKVE3
could be sticking to the sides of the tube used in the
cleavage reaction. To test this idea, CHIKVTrx-6XHis-E3
was purified through cobalt-affinity purification, which
is similar to nickel-affinity purification, except cobalt is
used in the column instead of nickel. This improved the
purity of CHIKVTrx-6XHis-E3, and the TEV cleavage reaction
was set up using fresh TEV. After the reactions were
completed, the mixture was transferred into fresh tubes,
and samples of the material from the sides of the old tubes
were made (see Figure 6).

Expression and nickel-affinity purification of the
recombinant protein from CHIKV
After the success with the expression and purification of
VEEVE3, the same techniques were applied to the purification of CHIKVE3. CHIKVTrx-6XHis-E3 was expressed at

Figure 3. Purification of VEEVE3. The expression of
VEEVTrx-6XHis-E3 at zero hours (lane 1) and two hours (lane 2)
at 37°C. The cell lysate containing VEEVTrx-6XHis-E3 (lane 3) was
purified through nickel-affinity purification (lane 4), cleaved with
TEV protease, and VEEVE3 was then purified by nickel-affinity
purification and anion-exchange purification (lane 5).

Figure 4. HSQC of VEEVE3-N15 at 4°C.
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The expression of CHIKVTrx-6XHis-E3 yielded similar
amounts of protein as the VEEVTrx-6XHis-E3 expression, and
the nickel-affinity purification produced large amounts
of relatively pure CHIKVTrx-6XHis-E3. Unfortunately, after
TEV cleavage and subsequent purification, the yield of
CHIKVE3 was very low.

Interestingly, the material from the sides of the tube
contain either CHIKVTrx-6XHis-E3, TEV, or both, and
possibly CHIKVE3. This could explain why there has been
poor cleavage efficiency and lack of CHIKVE3. If the TEV,
CHIKVTrx-6XHis-E3, or both are sticking to the sides, they
have less opportunity to contact each other for cleavage.
The CHIKVE3 would not be recovered because only the
liquid mixture is applied to the nickel column. It is likely

Figure 5. Purification of CHIKVE3. The expression of
CHIKVTrx-6XHis-E3 at zero hours (lane 1) and four hours (lane 2)
at 37°C. The cell lysate containing CHIKVTrx-6XHis-E3 (lane 3) was
purified through nickel-affinity purification (lane 4), cleaved with
TEV protease, and CHIKVE3 was then purified by nickel-affinity
purification (lane 5).

Lobigs, M., & Garoff, H. (1990). Fusion function of the
Semliki Forest Virus spike is activated by proteolytic
cleavage of the envelope glycoprotein precursor p62.
Journal of Virology, 64, 1233-1240.

Figure 6. TEV cleavage of CHIKVTrx-6XHis-E3 after cobalt
purification. CHIKVTrx-6XHis-E3 was cleaved using TEV (lane 1).
The reaction at four hours (lane 2), at eight hours (lane 3), after
22 hours (lane 4), and material stuck to the sides of the tube
(lanes 5 and 6) are shown.

that after cleavage CHIKVE3 becomes insoluble and sticks
to the sides of the tube. Investigation into different buffers
and different reaction tubes is needed to avoid this problem.

Conclusion
The optimal levels of VEEVTrx-6XHis-E3 expression at 37°C
were reached within two hours, and large amounts of
VEEVE3 were obtained from nickel-affinity purification
and anion-exchange purification. Expression in minimal
media of N15 labeled VEEVTrx-6XHis-E3 was successful, but
HSQC to determine the secondary structure was not as
a result of protein aggregation. More work is needed to
identify buffer conditions that will prevent aggregation.
The optimal levels of CHIKVTrx-6XHis-E3 expression at 37°C
were reached within four hours. However, CHIKVE3
appears to be sticking to the sides of the reaction tube,
so more research is needed to fix the problem and to
ensure that pure CHIKVE3 can be obtained and used for
structural analysis.
With further research, the structure of E3 from
the Venezuelan Equine Encephalitis Virus and the
Chikungunya Virus can be determined. This information
could be used by pharmaceutical companies to design
drugs with similar structures that could prevent infection
in much the same manner as E3. With a potential
treatment, concern about the development of the viruses
as biological warfare agents would be diminished, and the
quality of health of individuals in geographic areas where
the viruses persist would be greatly improved.
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